Katina Dorton is an experienced public company director. She currently serves on the Board of Directors of Fulcrum Therapeutics (Nasdaq: FULC), where she chairs the Audit Committee and serves on the Compensation Committee; the Board of Directors of TScan Therapeutics (Nasdaq: TCRX), where she Chairs the Audit Committee and serves on the Compensation Committee; and the Board of Directors of US Ecology (Nasdaq: ECOL), where she serves on the Audit Committee. She is currently Chief Financial Officer of Nodthera Inc.